PRECIGEN INC (PGEN) Stock Fundamental Analysis

NASDAQ:PGEN • US74017N1054

4.38 USD
-0.13 (-2.88%)
At close: Feb 20, 2026
4.39 USD
+0.01 (+0.23%)
After Hours: 2/20/2026, 8:00:01 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to PGEN. PGEN was compared to 520 industry peers in the Biotechnology industry. While PGEN seems to be doing ok healthwise, there are quite some concerns on its profitability. PGEN is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

  • In the past year PGEN has reported negative net income.
  • In the past year PGEN has reported a negative cash flow from operations.
  • In the past 5 years PGEN reported 4 times negative net income.
  • PGEN had a negative operating cash flow in each of the past 5 years.
PGEN Yearly Net Income VS EBIT VS OCF VS FCFPGEN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -100M -200M -300M -400M -500M

1.2 Ratios

  • PGEN's Return On Assets of -248.66% is on the low side compared to the rest of the industry. PGEN is outperformed by 90.60% of its industry peers.
  • PGEN has a worse Return On Equity (-1017.16%) than 79.46% of its industry peers.
Industry RankSector Rank
ROA -248.66%
ROE -1017.16%
ROIC N/A
ROA(3y)-45.76%
ROA(5y)-43.42%
ROE(3y)-82.57%
ROE(5y)-117.47%
ROIC(3y)N/A
ROIC(5y)N/A
PGEN Yearly ROA, ROE, ROICPGEN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -100 -200 -300 -400

1.3 Margins

  • PGEN has a Gross Margin of 30.32%. This is in the better half of the industry: PGEN outperforms 72.94% of its industry peers.
  • The Profit Margin and Operating Margin are not available for PGEN so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 30.32%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
PGEN Yearly Profit, Operating, Gross MarginsPGEN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -1K -2K -3K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

4

2. Health

2.1 Basic Checks

  • PGEN does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • PGEN has less shares outstanding than it did 1 year ago.
  • PGEN has less shares outstanding than it did 5 years ago.
  • There is no outstanding debt for PGEN. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
PGEN Yearly Shares OutstandingPGEN Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M
PGEN Yearly Total Debt VS Total AssetsPGEN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M

2.2 Solvency

  • Based on the Altman-Z score of -13.12, we must say that PGEN is in the distress zone and has some risk of bankruptcy.
  • PGEN has a Altman-Z score of -13.12. This is in the lower half of the industry: PGEN underperforms 77.35% of its industry peers.
  • PGEN has a Debt/Equity ratio of 2.22. This is a high value indicating a heavy dependency on external financing.
  • PGEN's Debt to Equity ratio of 2.22 is on the low side compared to the rest of the industry. PGEN is outperformed by 78.50% of its industry peers.
Industry RankSector Rank
Debt/Equity 2.22
Debt/FCF N/A
Altman-Z -13.12
ROIC/WACCN/A
WACC8.72%
PGEN Yearly LT Debt VS Equity VS FCFPGEN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M 400M

2.3 Liquidity

  • PGEN has a Current Ratio of 4.04. This indicates that PGEN is financially healthy and has no problem in meeting its short term obligations.
  • Looking at the Current ratio, with a value of 4.04, PGEN is in line with its industry, outperforming 48.37% of the companies in the same industry.
  • PGEN has a Quick Ratio of 3.95. This indicates that PGEN is financially healthy and has no problem in meeting its short term obligations.
  • The Quick ratio of PGEN (3.95) is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 4.04
Quick Ratio 3.95
PGEN Yearly Current Assets VS Current LiabilitesPGEN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

5

3. Growth

3.1 Past

  • The earnings per share for PGEN have decreased strongly by -204.76% in the last year.
  • The Revenue has grown by 59.20% in the past year. This is a very strong growth!
  • PGEN shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -46.64% yearly.
EPS 1Y (TTM)-204.76%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-1077.78%
Revenue 1Y (TTM)59.2%
Revenue growth 3Y-35.01%
Revenue growth 5Y-46.64%
Sales Q2Q%206.61%

3.2 Future

  • The Earnings Per Share is expected to grow by 33.15% on average over the next years. This is a very strong growth
  • Based on estimates for the next years, PGEN will show a very strong growth in Revenue. The Revenue will grow by 155.65% on average per year.
EPS Next Y-155.49%
EPS Next 2Y21.47%
EPS Next 3Y30.42%
EPS Next 5Y33.15%
Revenue Next Year312.21%
Revenue Next 2Y388.31%
Revenue Next 3Y267.77%
Revenue Next 5Y155.65%

3.3 Evolution

  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
PGEN Yearly Revenue VS EstimatesPGEN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 200M 400M 600M 800M 1B
PGEN Yearly EPS VS EstimatesPGEN Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -1 -2 -3

More info and screens

Find the best growth stocksShow best growing peers

1

4. Valuation

4.1 Price/Earnings Ratio

  • PGEN reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Also next year PGEN is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
PGEN Price Earnings VS Forward Price EarningsPGEN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
PGEN Per share dataPGEN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.2 -0.4 -0.6 -0.8 -1

4.3 Compensation for Growth

  • A more expensive valuation may be justified as PGEN's earnings are expected to grow with 30.42% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y21.47%
EPS Next 3Y30.42%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • PGEN does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

PRECIGEN INC

NASDAQ:PGEN (2/20/2026, 8:00:01 PM)

After market: 4.39 +0.01 (+0.23%)

4.38

-0.13 (-2.88%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-13
Earnings (Next)03-09
Inst Owners66.86%
Inst Owner Change17.52%
Ins Owners2.66%
Ins Owner Change-1.14%
Market Cap1.55B
Revenue(TTM)6.31M
Net Income(TTM)-425.87M
Analysts80
Price Target8.67 (97.95%)
Short Float %13.73%
Short Ratio9.96
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-500.32%
Min EPS beat(2)-993.91%
Max EPS beat(2)-6.73%
EPS beat(4)1
Avg EPS beat(4)-247.59%
Min EPS beat(4)-993.91%
Max EPS beat(4)14.22%
EPS beat(8)1
Avg EPS beat(8)-134.84%
EPS beat(12)2
Avg EPS beat(12)-89.42%
EPS beat(16)5
Avg EPS beat(16)-84.11%
Revenue beat(2)2
Avg Revenue beat(2)249.41%
Min Revenue beat(2)25.88%
Max Revenue beat(2)472.94%
Revenue beat(4)3
Avg Revenue beat(4)162.05%
Min Revenue beat(4)-13.58%
Max Revenue beat(4)472.94%
Revenue beat(8)3
Avg Revenue beat(8)64.9%
Revenue beat(12)3
Avg Revenue beat(12)31.35%
Revenue beat(16)3
Avg Revenue beat(16)4.6%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-51.51%
EPS NY rev (1m)0%
EPS NY rev (3m)-120.55%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-30.54%
Revenue NY rev (1m)0%
Revenue NY rev (3m)26.84%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 245.64
P/FCF N/A
P/OCF N/A
P/B 37.01
P/tB 66.98
EV/EBITDA N/A
EPS(TTM)-1.28
EYN/A
EPS(NY)-0.18
Fwd EYN/A
FCF(TTM)-0.21
FCFYN/A
OCF(TTM)-0.21
OCFYN/A
SpS0.02
BVpS0.12
TBVpS0.07
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -248.66%
ROE -1017.16%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 30.32%
FCFM N/A
ROA(3y)-45.76%
ROA(5y)-43.42%
ROE(3y)-82.57%
ROE(5y)-117.47%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.04
Health
Industry RankSector Rank
Debt/Equity 2.22
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 110.36%
Cap/Sales 47.63%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.04
Quick Ratio 3.95
Altman-Z -13.12
F-Score3
WACC8.72%
ROIC/WACCN/A
Cap/Depr(3y)86.13%
Cap/Depr(5y)70.81%
Cap/Sales(3y)87.22%
Cap/Sales(5y)63.93%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-204.76%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-1077.78%
EPS Next Y-155.49%
EPS Next 2Y21.47%
EPS Next 3Y30.42%
EPS Next 5Y33.15%
Revenue 1Y (TTM)59.2%
Revenue growth 3Y-35.01%
Revenue growth 5Y-46.64%
Sales Q2Q%206.61%
Revenue Next Year312.21%
Revenue Next 2Y388.31%
Revenue Next 3Y267.77%
Revenue Next 5Y155.65%
EBIT growth 1Y-12.91%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-1.14%
EBIT Next 3Y25.15%
EBIT Next 5YN/A
FCF growth 1Y-12.7%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-9.1%
OCF growth 3YN/A
OCF growth 5YN/A

PRECIGEN INC / PGEN FAQ

What is the fundamental rating for PGEN stock?

ChartMill assigns a fundamental rating of 3 / 10 to PGEN.


Can you provide the valuation status for PRECIGEN INC?

ChartMill assigns a valuation rating of 1 / 10 to PRECIGEN INC (PGEN). This can be considered as Overvalued.


What is the profitability of PGEN stock?

PRECIGEN INC (PGEN) has a profitability rating of 1 / 10.


What is the expected EPS growth for PRECIGEN INC (PGEN) stock?

The Earnings per Share (EPS) of PRECIGEN INC (PGEN) is expected to decline by -155.49% in the next year.